359 | Updated Results From Keynote‐b68: Pembrolizumab Every 6 Weeks in Participants With Relapsed or Refractory Classic Hodgkin Lymphoma or Primary Mediastinal B‐cell Lymphoma
Year: 2025
Type: article
Source: Hematological Oncology
Institutions: University of Cape Town, Groote Schuur Hospital, Policlinico San Matteo Fondazione, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Gdańsk Medical University, Federal Almazov North-West Medical Research Centre, National Medical and Surgical Center named after N.I. Pirogov, University Hospital Kralovske Vinohrady, Ankara University, Ospedale Vincenzo Cervello, Hospital Erasto Gaertner, Hospital de Câncer de Barretos, Kharkiv National Medical University, Masaryk University, University Hospital Brno, Ege University, Ege Üniversitesi Tıp Fakültesi Hastanesi, University of California, Los Angeles, Harbor–UCLA Medical Center, Merck & Co., Inc., Rahway, NJ, USA (United States)
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funder: Sanofi
OpenAlex ID: W4411329027